Bayer launches Verquvo in India, a novel treatment approved to reduce the risk of CVD fatalities

Bayer has launched vericiguat (Verquvo), a soluble guanylate cyclase (sGC) stimulator, in India. Vericiguat is indicated, along with guideline-based medical therapy, in adults with symptomatic chronic heart failure with reduced ejection fraction (less than …